Clopidogrel Bisulfate represents a pharmaceutically optimised salt form in which counter-ion selection modifies the physicochemical properties of the parent molecule without altering its core pharmacophore or intrinsic pharmacodynamic activity. The crystal lattice energy of Clopidogrel Bisulfate determines its thermodynamic stability, dissolution behaviour, and susceptibility to polymorphic transformation under manufacturing process conditions. PDE assessment for Clopidogrel Bisulfate in shared manufacturing facilities is based on the pharmacological activity of the parent active moiety, with the MACO calculation adjusted using the molecular weight ratio of free base or acid to salt form.
ICH Q3A qualification thresholds for impurities in new drug substances require toxicological qualification of individual impurities of Clopidogrel Bisulfate exceeding the reporting threshold (0.05% or 1 mg TDI, whichever is lower), identification threshold (0.10% or 2 mg TDI), and qualification threshold (0.15% or 2 mg TDI).
